Roche Holding AG
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Roche Holding AG develops, manufactures and markets pharmaceuticals and in vitro diagnostics worldwide. The company operates through its Pharmaceuticals and Diagnostics divisions; the Pharmaceuticals division offers prescription medicines addressing oncology, immunology, infectious diseases, ophthalmology, neuroscience, cardiovascular, renal and metabolic diseases, haemophilia, inflammatory and respiratory conditions; key products include monoclonal antibodies, antibody-drug conjugates and targeted therapies such as Tecentriq, Perjeta, Avastin, Hemlibra and Actemra; the Diagnostics division provides professional diagnostics systems and reagents for clinical chemistry, immunoassays, molecular diagnostics, tissue diagnostics and diabetes care including Accu-Chek glucose monitoring; additional offerings encompass point-of-care tests such as the recently FDA-cleared Bordetella infection diagnostic and sequencing technologies like those achieving Guinness World Record advances in 2025. Roche Holding AG maintains a global presence with operations in more than 130 countries, substantial manufacturing and R&D facilities in the United States including Genentech as a wholly owned subsidiary and a majority stake in Chugai Pharmaceutical in Japan. Founded in 1896 and headquartered in Basel, Switzerland, the company pursues recent strategic expansions including a USD 50 billion investment over five years announced in 2025 for new US R&D centres in Massachusetts focused on AI and cardiovascular-metabolic research, expanded manufacturing in Indiana for continuous glucose monitoring and weight loss medicines, gene therapy facilities in Pennsylvania and upgrades across multiple states creating over 12,000 jobs; it entered a definitive merger agreement in September 2025 to acquire 89bio for up to USD 3.5 billion to bolster its CVRM portfolio with pegozafermin for moderate to severe MASH; other moves encompass the 2024 acquisition of Carmot Therapeutics for USD 2.7 billion, 2023 purchase of Televant Holdings for USD 7.1 billion, partnerships like the antibody-drug conjugate deal with Innovent Biologics and licensing of CDK inhibitors from Regor Pharmaceuticals.
Company News
Roche Partners With China's Hansoh in Deal That Could Top $15 Billion
Roche to unveil lung, breast cancer data at ESMO 2026
Roche Gets FDA Approval for Enspryng in Thyroid Eye Disease
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
Roche Expands Obesity Pipeline With Rona's RNAi Candidate
Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics
Roche Reports Positive Phase III Data on Eye Drug, FDA Accepts BLA
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
Roche Gets FDA Approval for Another Label Expansion of Tecentriq
BAYRY vs. RHHBY: Which Stock Should Value Investors Buy Now?
Roche Holding AG (RHHBY) Discusses Pharma Strategy, R&D Excellence, AI in Drug Development, and Pipeline Updates Across Key Therapeutic Areas Transcript
Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy
Roche outlines plans to move towards autonomous AI labs
NTHM's Index Rebalance Puts Thematic Rotation to Work
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?
Roche signs drug-discovery deal with Atavistik Bio worth up to $2 billion
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
Roche: Latest Obesity Data Suggests Pharma Is In Line To Become Global GLP-1 Player
Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease